prikaz prve stranice dokumenta Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
  Preuzmi
PDF 881.67 KB
Znanstveni rad - Izvorni znanstveni rad
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
Biomedicines, 12 (2024), 12; 2902. https://doi.org/10.3390/biomedicines12122902
Aurer, Igor; Jakšić, Ozren; Bašić-Kinda, Sandra; Mišura-Jakobac, Karla; Sinčić-Petričević, Jasminka; Novaković-Coha, Sabina; Galušić, Davor; Holik, Hrvoje; Valković, Toni; Županić-Krmek, Dubravka; Hude-Dragičević, Ida; Milunović, Vibor; Pejša, Vlatko

Citirajte ovaj rad

Aurer, I., Jakšić, O., Bašić Kinda, S., Mišura Jakobac, K., Sinčić Petričević, J., Novaković Coha, S. ... Pejša, V. (2024). Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases. Biomedicines, 12. (12). doi: 10.3390/biomedicines12122902

Aurer, Igor, et al. "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases." Biomedicines, vol. 12, br. 12, 2024. https://doi.org/10.3390/biomedicines12122902

Aurer, Igor, Ozren Jakšić, Sandra Bašić Kinda, Karla Mišura Jakobac, Jasminka Sinčić Petričević, Sabina Novaković Coha, Davor Galušić, et al. "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases." Biomedicines 12, br. 12 (2024). https://doi.org/10.3390/biomedicines12122902

Aurer, I., et al. (2024) 'Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases', Biomedicines, 12(12). doi: 10.3390/biomedicines12122902

Aurer I, Jakšić O, Bašić Kinda S, Mišura Jakobac K, Sinčić Petričević J, Novaković Coha S, i sur.. Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases. Biomedicines [Internet]. 20.12.2024. [pristupljeno 23.12.2024.];12(12). doi: 10.3390/biomedicines12122902

I. Aurer, et al., "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases", Biomedicines, vol. 12, br. 12, Prosinac 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:306597. [Citirano: 23.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:306597
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
AutorIgor Aurer
AutorOzren Jakšić
AutorSandra Bašić-Kinda
AutorKarla Mišura-Jakobac
AutorJasminka Sinčić-Petričević
AutorSabina Novaković-Coha
AutorDavor Galušić
AutorHrvoje Holik
AutorToni Valković
AutorDubravka Županić-Krmek
AutorIda Hude-Dragičević
AutorVibor Milunović
AutorVlatko Pejša
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks. Alternative schedules of chlorambucil enable the administration of higher total chlorambucil doses, and have better antileukemia activity. So far, evidence on the feasibility of combining obinutuzumab with alternative chlorambucil schedules is lacking. We performed this retrospective analysis to analyze real life outcomes in chronic lymphocytic leukemia patients receiving a combination of obinutuzumab with different chlorambucil schedules. Methods: This was a retrospective survey performed in order to analyze the feasibility and efficacy of different obinutuzumab and chlorambucil combinations in a real-life setting. Patients receiving this combination as a front-line therapy for chronic lymphocytic leukemia in participating centers, outside of clinical trials, in 2017 and 2018 were included. Results: Seventy-three patients fulfilling entry criteria were identified. Their median age was 76 years, and ranged from 58 to 90 years. The median follow up time was 59 months. The response rate was 89%, with a median progression-free survival time of 27 months, and an overall survival time of 49 months. Chlorambucil was administered as planned in 15 of the 22 (79%) patients treated with chlorambucil pulses every 2 weeks; in 15 of the 42 (34%) patients treated with 7-day courses of chlorambucil administered every 4 weeks; and in 0 of the 10 patients treated with a continuous high dose of chlorambucil (p = 0.002). Changes in treatment schedules were made due to side effects. The progression-free and overall survival rates were similar between the three groups. Conclusions: The combinations of obinutuzumab with more intensive chlorambucil schedules are less feasible, preventing the administration of the intended higher total dose of chlorambucil, and do not improve outcomes in comparison to chlorambucil pulses administered every 2 weeks.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 12, br. 12, 2902
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12122902
URN:NBNurn:nbn:hr:184:306597
Datum objave publikacije2024-12-20
URL dokumentahttps://www.mdpi.com/2227-9059/12/12/2902
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-12-23 08:03:56